KCT0004189已完成未知
eoadjuvant nivolumab for operable esophageal squamous cell carcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria
- •1.Histologically confirmed esophageal squamous cell carcinoma
- •2.Clinical stage T2N0 (invasion to muscularis propria) or T3N0 (invasion to adventitia)
- •3.No prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
- •4.Age 19 years or older
- •5.ECOG performance 0 or 1
- •6.A female participant is eligible to participate if she is not pregnant, not breastfeeding, and agrees to follow contraceptive guideline.
- •7.A male participant must agree to use contraception during the treatment period and for at least 180 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period.
- •8.The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
- •9.Subjects who have been fully informed or the nature of the study through the informed consent form by the investigator and gave their consent for voluntary participation in the study
- •10. If there is sufficient organs and bone marrow function in the test within 14 days of the start of treatment.
- •- Adequate organ function as evidenced by the following: Hb = 8.0g/dl, Absolute neutrophil count = 1.0 x 109/L total bilirubin =1.5 UNL except subjects Gilbert’s syndrome (=3 X ULN); AST and/or ALT < 2.5 UNL; creatinine clearance = 40 mL/min by the Cockcroft-Gault formula [male: weight (kg) x (140-age) / (72 x serum creatinine), female: weight (kg) x (140-age) x 0.85/(72 x serum creatinine)]
排除标准
- •Exclusion Criteria
- •1.Has received a live vaccine within 30 days prior to the first dose of study drug. (eg: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine). Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed.
- •2.Patients enrolled in other clinical studies(However, observational studies are irrelevant)
- •3.Ineligibility or contraindication for esophagectomy
- •4.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •5.Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, well differentiated thyroid carcinoma, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. In addition, early gastric or bladder cancer that completely resected with endoscopic resection are not excluded, even if the procedure was performed within 2 years.
- •6.Has severe hypersensitivity and adverse events (=Grade 3) to nivolumab and/or any PD-1/PD-L1 inhibitors.
- •7.Active or previously documented autoimmune disease or inflammatory disease (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [Excluding diverticulum], Systemic lupus erythematosus, sarcoidosis syndrome or Wegener syndrome [Granulomatosis with polyangiitis, Gaves disease, rheumatoid arthritis, hypophysitis, uveiti and the like] include). Exceptions to this criterion include:
- •- Patient with vitiligo or alopecia
- •- Patients with hypothyroidism who are receiving hormone replacement therapy stably. (e.g., after Hashimoto`s syndrome)
- •- a chronic skin disease that does not require full-body therapy.
- •- the celiac disease are controlled by food.
- •- Patients without active disease within the past five years can only be selected after consultation with a clinical trial physician.
- •8.Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- •9.Has an active infection requiring systemic therapy.
- •10.Has a known history of Human Immunodeficiency Virus (HIV)
- •11.TB (clinical assessment includes clinical past history, physical exam and radiological findings, and TB testing on local care), Active infection, such as hepatitis C or human immunodeficiency virus (positive HIV 1/2 antibody). However, patients with hepatitis C (HCV) antibody positive are only suitable if the polymerase chain reaction to HCV RNA is negative. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
- •12.Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •13.Is pregnant or breast feeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days af
研究者
相似试验
Unknown
2 期
Neoadjuvant Nivolumab for Operable Esophageal CarcinomaEsophageal Squamous Cell CarcinomaNCT03987815Samsung Medical Center20
进行中（未招募）
1 期
Eoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial)Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusCTIS2022-500966-82-00Karolinska University Hospital1,010
进行中（未招募）
1 期
Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusMedDRA version: 21.1Level: LLTClassification code 10025899Term: Malignant neoplasm of esophagusSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025901Term: Malignant neoplasm of esophagus, unspecifiedSystem Organ Class: 100000004864EUCTR2020-000149-15-IEKarolinska University Hospital1,020
进行中（未招募）
1 期
Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusMedDRA version: 21.1Level: LLTClassification code 10025899Term: Malignant neoplasm of esophagusSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025901Term: Malignant neoplasm of esophagus, unspecifiedSystem Organ Class: 100000004864EUCTR2020-000149-15-SEKarolinska University Hospital1,020
进行中（未招募）
1 期
Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusMedDRA version: 21.1Level: LLTClassification code 10025899Term: Malignant neoplasm of esophagusSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025901Term: Malignant neoplasm of esophagus, unspecifiedSystem Organ Class: 100000004864EUCTR2020-000149-15-NOKarolinska University Hospital1,020